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Polynomial ﬁttingRheumatoid arthritis (RA) is a chronic autoimmune disease resulting in joint inﬂammation, pain, and eventual
bone loss. Bone loss and remodeling caused by symmetric polyarthritis, the hallmark of RA, is readily detectable
by bone mineral density (BMD) measurement using micro-CT. Abnormalities in these measurements over time
reﬂect the underlying pathophysiology of the bone. To evaluate the efﬁcacy of anti-rheumatic agents in animal
models of arthritis, we developed a high throughput knee and ankle joint imaging assay to measure BMD as a
translational biomarker. A bone sample holder was custom designed for micro-CT scanning, which signiﬁcantly
increased assay throughput. Batch processing 3-dimensional image reconstruction, followed by automated
image cropping, signiﬁcantly reduced image processing time. In addition, we developed a novel, automated
image analysis method to measure BMD and bone volume of knee and ankle joints. These improvements
signiﬁcantly increased the throughput of ex vivo bone sample analysis, reducing data turnaround from 5 days to
24 hours for a study with 200 rat hind limbs. Taken together, our data demonstrate that BMD, as quantiﬁed by
micro-CT, is a robust efﬁcacy biomarker with a high degree of sensitivity. Our innovative approach toward evalu-
ation of BMD using optimized image acquisition and novel image processing techniques in preclinical models of
RA enables high throughput assessment of anti-rheumatic agents offering a powerful tool for drug discovery.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune
disease inwhich the immune system triggersmultiple inﬂammatory re-
sponses against self-antigens, resulting in erosion of cartilage and bone
in and around the peripheral joints [1]. The pathogenesis of RA includes
a complex inﬂammatory response involving innate and adaptive
immune cells, proinﬂammatory cytokines, and autoantibodies thatrck Research Laboratories, 33
17 992 2487.
ng).
. This is an open access article underinﬁltrate the synovia causing ﬂuid accumulation, pain, and bone dam-
age in the affected joints [2,3].
Animal models of RA have been used extensively to interrogate
the distinct mechanisms of disease pathology and identify potential
biological targets in pursuit of novel therapeutics. Collagen induced
arthritis (CIA) is a widely used rodent model of induced arthritis. The
rat CIA model exhibits multiple facets of human disease including pro-
found cartilage degradation, dependence on complement immunity,
periarticular inﬂammation, and bone resorption [4]. Following collagen
injection, rats display a severe polyarthritic phenotype consisting of
swollen extremities, cartilage degradation, and eventual loss of joint
function, which is, in some aspects, similar to RA [5,6,7]. The reproduc-
ibility, low variability, and rapid disease onset of this model make it athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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paw thickness is a routinely used surrogate marker of inﬂammatory pa-
thology in this model [5,7,9]. In the rat CIAmodel, approximately 80% of
animals develop visually observable edema in the ankles and paws,
while about 20% of animals develop visually observable edema in the
knee [8–10]. However, evenwhen edema is not present, cellular inﬁltra-
tion, cartilage degradation, and structural changes to bone occur at the
knee and other affected joints [8,10]. While useful, paw thickness does
not reveal the underlying structural changes to the bone caused by dis-
ease since paw thickness only directly measures edema. Assessment of
bonemorphology by imaging is amore sensitive and translational read-
out; damage to its structural integrity, and in particular, periarticular
demineralization, points to hyper-activation of osteoclast activity,
which is a critical component of RA [2].
Over the last two decades, imaging hasmademajor advances in early
diagnosis and therapeutic monitoring of RA [11]. In the clinic, X-ray
radiography is the standard for imaging-assisted diagnosis of RA. Also
based on X-ray technology, computed tomography (CT) has demon-
strated higher sensitivity for quantifying bone erosions in RA patients,
due to its 3-D visualization perspective [12]. It is ideal for bonemeasure-
ments due to its high spatial resolution and the natural contrast be-
tween bone and soft tissue. A reduction in bone mineral density
(BMD), an important biomarker of disease assessed by CT, indicates
poor prognosis for patients with early stages of RA [13–15]. CT has also
been demonstrated to be an excellent tool for assessment of bone dam-
age in preclinical rodentmodels of RA due to its high reproducibility and
inherently quantiﬁable properties [16,17]. Radiological examination has
been applied successfully to monitor progression of RA and osteoarthri-
tis in various preclinical models to gain a deeper understanding of
the pathophysiology of disease [18–25]. Many metrics are used to
track disease progression, including bone volume changes, bone surface
roughness, erosion scoring, 3-D tissue morphometry, and BMD mea-
surements, as measured by X-ray, DEXA, or micro-CT [18–25]. Despite
widespread use of both micro-CT and DEXA to gather BMD measure-
ments, it has been demonstrated, in at least one animal model, that
the volumetric BMD measured by micro-CT is more sensitive than the
2-D BMD measurements acquired by DEXA [24].
Automated analysis can dramatically increase throughput, so special
attention has been given to performance tuning the analysis procedure
by developing new automation methods. For example, Barck et al. de-
scribe an automated method to measure BMD of the paw joints in
mice and Huber et al. describe automated BMD measurements of
femur in human [23,26]. However, other biomarkers, such as changes
in bone architecture, are more heavily emphasized in the literature on
automated bone analysis. There are examples of automation techniques
that can separate trabecular bone from cortical bone or segment trabec-
ular bone using high resolution images [27,28]. An in vivomethod using
registration techniques to detect differences in bone lesion volume in a
rat model using magnetic resonance has also been described [29].
Segmenting speciﬁc bone components, such as trabecular or cortical
bone, and then measuring shape and attributes such as 2-D area and
3-D volume, or bone erosion are the main analysis endpoints in these
publications. Of note, the automation techniques in these studies were
not able to avoid manually separating their regions of interest (ROIs)
from their samples; instead, ROIs were either prepared prior to imaging
or were manually segmented from a larger area after imaging and be-
fore automated image analysis was used to extract measurements.
Herein,we describe a high-throughputmethod to evaluate BMDand
track volume changes of peripheral joints for pharmacological assess-
ment of drug candidates to support discovery of novel therapeutics.
Our objective was to apply BMD measurements of the knee and ankle
joints in the rat CIA model as a rapid and efﬁcient biomarker for drug
screening and optimization. The methods we detail had to replicate
the sensitivity and accuracy of slower acquisition processes, while
speeding up work-ﬂow. The automated analysis method also needed
to correlate with manual analysis and show high reproducibility fromstudy to study. To achieve this goal, we developed a streamlined process
to image eight bone samples simultaneously and perform batch image
reconstruction and automated image cropping. In addition, we demon-
strate a novel automated method of combining image processing
techniques, such as intensity thresholding and skeletonization, with
mathematical techniques in curve ﬁtting and curvature calculations, to
ﬁnd and place a bounding box around the ROIs in CT images quickly
and consistently. The algorithm can process individual images or entire
data sets and provides various metrics of interest including volume and
mean intensity of Hounsﬁeld units of the bone ROI within the bounding
box. Thismanuscript further expounds newmethods of data acquisition
and analysis that utilize the predictive potential of BMD assessment as it
relates to RA outcome and therapeutic treatment in the rat CIA model.
Materials and methods
Development
Micro-CT: acquisition, image reconstruction, and cropping
Conical tubes containing ﬁxed rat hind limbs stored in 70% ethanol
solution were loaded into the micro-CT holder. Samples were posi-
tioned symmetrically on the perimeter of the holder for equal X-ray
beam exposure, with a phantom located in the middle of the holder
(Fig. 1B). CT scans were acquired as described in Haines et al. (2009)
with the exception that the three dimensions of the image data set
(X, Y, and Z) were adjusted to 1000 × 900 × 1300 slices at 100 μm
cubic voxel dimensions and scaled to Hounsﬁeld units (HU) [30]. The
reconstructed data were then cropped into images containing a single
bone sample, using MATLAB (MathWorks, Inc., Natick, MA, USA) soft-
ware to automate this process.
Automated image analysis and manual correction
The CT images were downsampled and thresholded to 300 HU. We
chose this range to be consistent between studies and because it
showed the best dynamic range while still excluding soft tissue. Impor-
tantly, the bone samples on which this threshold is applied undergo
rapid formalin ﬁxation and are then stored in ethanol ﬁlled conical
tubes. This threshold is designed to take the tubes, scanning holder,
and ethanol into account. After thresholding, a morphological closing
operation was applied to the bone mask to ﬁll the holes, and this resul-
tant mask was skeletonized to obtain the main shape of the hind limb
bone. A 6th degree polynomial curvewasﬁtted using a Chebyshev poly-
nomial, as detailed previously [31]. The curvature of the skeleton was
calculated and the peaks of maximum curvature were found, using a
previously published equation [32]. Using the location ofmaximumcur-
vature, segmentation of the knees and ankles was performed by placing
predeﬁned boxes of sizes [X, Y, Z] around each ROI. The two knee and
ankle joint regions of interest at X, Y, and Z were set to 15 × 15 ×
15 mm and 13 × 13 × 13 mm, respectively. These bounding boxes
were placed by aligning the center point of the turning point of the
joint (Figs. 2A, B, C). After box placement, the bone inside is quantiﬁed
using thresholding to obtain volume and HU data for our desired ﬁnal
output: BMD of knee and ankle regions. By thresholding the box, only
the bone is selected as our ROI; air and other materials are excluded
from our measurements. We evaluate BMD as bone mineral content
(mg)/bone region (ROI in cm3) and track volume of the ROI as well.
After automated analysis was complete, cross-sectional views of the
boxes were exported as 2-D image ﬁles for visual inspection to ensure
that the algorithm worked properly (Fig. 2D) and a master Excel sheet
was generated containing the volumes and average HUs for the ROIs
(Fig. 2E). Bounding box placement was visually reviewed and samples
were manually re-analyzed if the boxes were misplaced or if samples
were not analyzed correctly using Amira®5.4.2 image analysis software
(Mercury Computer Systems, Inc., Chelmsford, MA). Detailed methods
are provided in the Supplementary methods section.
Fig. 1.Micro-CT imaging of rat hind limb samples. (A) The design of the conical tube holder with 8 bone samples and a spherical phantom loaded for scanning. Each 50 mL conical tube
contains a single rat hind limb sample ﬁxedwith formalin prior to being transferred to ethanol. (B) A representative cross-section image of a single scanwith 8 ethanol-ﬁlled conical tubes
with hind limb samples and a phantom in the middle.
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The micro-CT sample images were acquired together with a 5-core
density phantom custom designed for the sample holder. The phantom
is a miniaturized clinical Mindways Model 3 solid calibration phantom
(Mindways Software, Austin, TX, USA). The cylinder shaped phantom
has a diameter of 20 mm, and each core has a diameter of 6 mm
(Fig. 3A). The length spans the whole ﬁeld of view longitudinally. The
center of each core, that contains approximately 490 pixels per sliceFig. 2. Automation of BMD analysis of the rat hind limb using a MATLAB-based tool. (A) On th
largest Euclidean distance to the surface were calculated and traced in blue. The right image sho
in red. (B) Plot shows peaks that represent the knee, ankle, and paw joints, respectively, as ident
of knee and ankle joints within the smallest boxes in green. The larger bounding boxes are plac
entire joint and adjacent bone. (D) Cross-sectional views of knee and ankle boneswithin the bou
a quality controlmeasure after analysis is complete. (E) Anexample of data automatically gener
ID, bone volume, and mean HU. (F) Correlation between automated and manual analysis.(diameter = 2.5mm), was taken as a core sample for density measure-
ment (Fig. 3 B, area inside the ring). The CT intensity value was scaled to
Hounsﬁeld units (HU) andwas converted to an equivalent bonemineral
density (mg/cm3 K2HPO4) using the in-scan calibration phantom.
The density phantom is referred to as K2HPO4 equivalent density
phantom with densities equivalent to−51.8, −53.40, 58.90, 157.00,
and 375.80 mg/mL of K2HPO4 in water. This phantom is functionally
equivalent to hydroxyl apatite phantoms in the clinical settings [33,e left, skeletonization of the image showing points which reside in the bone and have the
ws a 6th degree parametric Chebyshev polynomial curve ﬁtted to the data and is overlaid
iﬁed by the curvature of the hind limb. (C) Chebyshev polynomial ﬁt showing center points
ed and aligned based on the smaller boxes in the centers around the peaks to include the
nding boxes are generated and saved during automated analysis to conﬁrm positioning as
ated by theMATLAB tool upon analysis completion. Themaster Excel sheet includes sample
Fig. 3. Phantom and core sample generation for BMD analysis. (A) Cross section of the density phantom in the holder chamber. Note the center core has similar density to the matrix.
(B) Visual marks left by automated analysis program. The MATLAB program created high density rings in the phantom image after sampling the voxels inside the density cores to offer
a visual clue for quality control.
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regression, similar to past approaches [34], Intercept:
a ¼ y− bxþ y0 þ a0
Slope:
b ¼
X
xi− xð Þ yi− yþ y0ið ÞX
xi− xð Þ2
þ b0
where x is the K2HPO4 concentration, y is the HU, and y0 is the displaced
water, y0 (constants for each rod supplied by themanufacturer). i is from
1 to 5 for the phantom cores. a0 and b0 are constants also supplied by the
manufacturer for thewater displacement factors added back to the inter-
cept and slope after the regression, respectively. A linear regression func-
tion is then generated for each scan. When the function is used for
interpolating the mineral density from sample HU, the linear equation
ysample ¼ bxsample þ a
was used. Here, xsample is the CT number from the sample in Hounsﬁeld
unit, and ysample is the corresponding bone mineral concentration equiv-
alent to K2HPO4 concentration water.
An automated MATLAB program was developed internally to seg-
ment the cores of the phantoms and generate the linear equations. The
program searched for all images, then iteratively looked for the phantom
images in the scans, localized the cores, generated the linear equations,
and converted the CT intensities in Hounsﬁeld units from the previous
steps to the mineral densities. The Hough transformation designed to
identify circles was again used to localize the cores in the phantom im-
ages. Once localized, the intensity values of the cores were determined
by averaging all voxel values in the ROIs. To ensure accuracy of the phan-
tom segmentation, a new set of phantom images were generated with
high intensity ring images that can be visually inspected in 3-D visualiza-
tion software such as Amira®. For each sample, BMDwas then calculated
based on the average HU using the respective linear equation.
In vivo studies
Animal use and care
Female Lewis rats, aged 6–7 weeks, were acquired from Harlan Lab-
oratories (Indianapolis, IN, USA), and housed two per cage. Animals had
access to drinking water and standard rodent chow ad libitum, and
were acclimated for 5 days before experiments began. Rats were en-
rolled into studies between ages 7 and 8 weeks, once they reached a
body weight between 125 and 150 g. These experiments were conduct-
ed in accordancewith federal animal care guidelines and all procedureswere reviewed by the Institutional Animal Care and Use Committee
(IACUC) of Merck Inc.
Induction of arthritis
Collagen induced arthritis was induced in rats using methods modi-
ﬁed from those described previously [7,9]. The animals were sensitized
on day 1 with two intradermal injections of 0.9 mg/rat type II bovine
collagen (Elastin Products, Owensville, MO, USA) emulsiﬁed in incom-
plete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, USA) at the tail
base (sub-cutaneous bolus, 2 sites, 150 μL each). The animals were chal-
lengedwith a second boost of the same collagen emulsion on day 7. The
rats exhibit initial signs of inﬂammation starting on day 11 and reach
maximum paw swelling around day 16. Paw thickness measurements
from both limbs were collected throughout the study using precision
mechanical calipers.
Characterization of CIA model and BMD in cross-sectional peel-off
paradigm
Three non-arthritic controls and 10CIA animalswere euthanized per
day on days 4, 9, 11, 14, 16, 23, and 30 post-disease induction. Paw
thickness was evaluated in vivo throughout the course of the study.
Post-necropsy, hind limbs were excised withmuch of the soft tissue re-
moved. Then, samples were ﬁxed in 10% Neutral Buffered Formalin
(NBF) for 24 h, then stored in 70% ethanol in 50 mL conical tubes, and
ﬁnally imaged with micro-CT.
Therapeutic and prophylactic treatment in rat CIA model
Dexamethasone (Sigma-Aldrich, St. Louis, MO, USA)was dissolved in
vehicle 1:9 PEG 400:10% Tween 80 and 6-α Methyl Prednisolone
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 10% Tween 80.
The rats were stratiﬁed into 3 groups: Non-arthritic control, CIA arthritic
control, and either Dexamethasone (DEX) or Prednisolone. Non-arthritic
control animals received intradermal injection of phosphate buffered sa-
line (PBS) vehicle in lieu of bovine collagen. The non-arthritic vehicle
control (n= 6) and CIA arthritic control (n= 10) groups received vehi-
cle (1:9 PEG 400:10% Tween 80) for Dexamethasone experiments or ve-
hicle (10% Tween 80) for Prednisolone experiments in lieu of DEX or
Prednisolone respectively. DEX or Prednisolone was administered orally
at 0.3 mg/kg quaque die (QD) or 3 mg/kg bis in die (BID), respectively
(n = 6 animals). The animals were sacriﬁced and the hind limbs were
excised on day 30 and BMDwas analyzed ex vivo. In the therapeutic par-
adigm, dosing started on day 17, stratiﬁed based on day 16 average hind
paw thickness values. A prophylactic treatment paradigmwas also eval-
uated, in which dosing started on day 1, before disease induction. In ei-
ther paradigm, dosing continued until necropsy on day 30 when bone
samples were collected for BMD and histological analysis.
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Preserved and decalciﬁed samples of ankles and knees were
trimmed, processed and embedded in parafﬁn blocks and sectioned. Se-
lected sections were stained with Toluidine Blue (Bolder BioPATH, Inc,
Boulder, CO, USA) for subsequent microscopic evaluation. A veterinary
pathologist scored the sections of knee and ankle for joint inﬂamma-
tion, pannus formation, cartilage destruction, cartilage damage, and
bone resorption, using severity grades: 1 = very slight, 2 = slight,
3 = moderate, 4 = marked, and 5 = severe.
Testing robustness of analysis techniques
To test accuracy and precision, we performed two follow-up exper-
iments. We postulated that different amounts of long bone or other
bones adjacent to the joints could potentially add signiﬁcant variability
to BMD measurements. Typically, our box sizes are 15 × 15 × 15 mm3
for knee and 13 × 13 × 13 mm3 for the ankle. Our ﬁrst experiment var-
ied box size±1 × 1 × 1mm3 for both joints. For knee, this is a change of
18–21% and for ankle it is a 21–24% change in total bounding box size.
We compared the various box sizes to our original box size using 20
rats: non-arthritic vehicles (N=6), CIA vehicle (N= 8), and DEX treat-
ed CIA (N= 6), for a total of 40 limbs.
In our next experiment, to measure the imaging endpoint reproduc-
ibility, a test–retest study of 20 subjects, was done on two separate
days TEST (day 0) and RETEST (day 3). 6 non-arthritic control, 8 CIA
arthritic, and 6 DEX treated CIA animals' limbs were scanned, recon-
structed, cropped, and auto-analyzed (20 animals, left and right
limbs = 40 samples).
Statistical methods
To statistically analyze the 30-day cross-sectional peel-off study in
the rat CIA model, we apply a two-way cell-mean model:
y ¼ μ i j þ εi jk
where μij characterizes themean of treatment i at time point j, k is index
of subject k for treatment I at time point j. Note that this model ad-
dresses our questions better than the conventional two-way ANOVA
model. We are not particularly interested in the interaction between
time and treatment, which characterizes the overall trend differences
between two treatments over the time course in the two-way ANOVA
model. Instead, we are interested in the differences between treatments
(CIA vs. non-CIA) at all the time points. The cell-mean allows us to con-
veniently build the linear statistical contrasts to estimate the mean
treatment differences and their standard error at each time point, there-
fore, the statistical signiﬁcance of the differences.
For the 30 day treatment studies, a one-way ANOVA model is ap-
plied; in this type of study, there is a response (dependent variable)
and treatments with multiple levels (independent variables):
Y ¼ a0 þ μ i þ εi j
where a0 is the overall mean, i is the index of treatment and j is the
index of the subject.
From this model, one can estimate the variance of the data and com-
pare the means of treatments. Post-hoc t-tests were performed on all
treatment studies using Bonferroni correction.
To assess the robustness, or reproducibility of quantitative measure-
ments, it is best to not be limited by using only one statistical method,
but rather to apply and compare several methods, as suggested by
Krummernauer andDoll [35]. Consequently,we applied the following, ar-
guably the most widely-used statistical methods for test–retest analysis:
• Bland–Altman plot [36]: a plot of the difference versus the mean of
TEST and RETEST, with a 95% limit of agreements. This plot provides
information of bias between the two sets of measurement, and as-
sesses if the two sets of measurement are interchangeable or if there
is a systemic trendof the differences against themeanmeasurements;• Pearson correlation coefﬁcient: this metric quantiﬁes the linear corre-
lation of the two sets of measurements;
• Intraclass correlation coefﬁcient: this metric quantiﬁes how much
TEST and RETEST resemble each other within a subject.
• Coefﬁcient of Variance (CV): this metric is characterized by the
variance of the differences divided by the overall mean, which quan-
tiﬁes how big the average differences are relative to the mean
measurements.
Results
Optimization of CT scan and image processing
The conical tube holder was built to circumvent handling formalin-
soaked hind limb samples. Micro-CT scanning was performed on sam-
ples while still in collection tubes (as shown in Fig. 1). This increased
our efﬁciency by reducing scan time from 4 h to about an hour for
200 samples. The batch reconstruction system by Acceleware signiﬁ-
cantly reduced reconstruction time to about 3 min per scan. We devel-
oped a MATLAB based cropping tool that writes individual images to
Analyze format; these cropped image ﬁles are much smaller and easier
to work with using the downstream image analysis software.
Automated selection of ROIs and data output
To evaluate changes in BMD in and around the joint in arthritic bone
samples, we developed a fully automated analysis method that utilized
a MATLAB platform with only a single line of input code required to run
analysis for the entire study (refer to Fig. 2 for process ﬂow). There
were typically about 2–5% of samples that needed to be manually ana-
lyzed due to incorrect positioning. Excluding incorrectly analyzed sam-
ples, there was an excellent correlation between manual and automated
BMD analysis, for example, R2 = 0.98 (Fig. 2F) for the ankle. For a study
of 200 samples with a 5% failure rate, automated analysis with manual
analysis of the 10 failed samples would take ~5.5 h. If only manual analy-
sis had been used, the same number of samples would have taken over
four full 8-hour work days. The automation saves even more time since
the executed script can run in the background or overnight.
Cross-sectional assessment of BMD in rat CIA model
To characterize and better understand disease pathology in the rat
CIA model, we ran a 30-day cross-sectional peel-off study (Fig. 4). For
non-arthritic animals, knee joint and surrounding bone BMD increased
signiﬁcantly from 476±15mg/mL on day 3 to 560±8mg/mL (mean±
SEM) on day 23 while ankle joint BMD changed from 663 ± 11 to
691± 6mg/mL during the same period. CIA animals showed signiﬁcant-
ly less dense bone 16 days after collagen injection compared to control
animals. By day 30, CIA knee BMD was 479 ± 4 mg/mL and CIA ankle
BMDwas reduced to 604± 4mg/mL (Figs. 4B & D). There was also a de-
crease in the knee volume by day 30 (249 ± 5 mm3) in the CIA animals
compared to control bone volume (294± 9mm3). In the ankle, howev-
er, bone volume in CIA animals increased to 194 ± 4mm3 compared to
non-arthritic ankle bone volume 156 ± 2 mm3. Non-arthritic paw
thickness measurements remained relatively consistent at 3.43 ±
0.04 mm on day 4 and 3.50 ± 0.06 mm on day 30. In contrast, CIA
paw thickness signiﬁcantly increased from 3.46 ± 0.02 mm on day 4
to 5.42 ± 0.23mm on day 14 and was stable until day 30, with average
readings of 5.36 ± 0.08 mm (Figs. 4E & F).
Therapeutic treatment assessment using BMD in rat CIA model
Dexamethasone and Prednisolone, two anti-inﬂammatory agents
with established efﬁcacy in preclinical animal models of inﬂammation,
Fig. 4. Characterization of BMD reduction and changes in bone volume in the rat CIA model. A cohort of female rats, aged 7–8 weeks, was injected with either type II bovine collagen in
incomplete Freund's adjuvant, or PBS as non-arthritic controls. Ten CIA and three non-arthritic animals were sacriﬁced at days 4, 9, 11, 14, 16, 23, and 30 and hind limb samples were col-
lected for bone analysis. Paw thickness wasmeasured prior to takedown. BMD and bone volume of the knee and ankleweremeasured usingmicro-CT. (A) Bone volume of knee ROI of CIA
and non-arthritic controls shown. There is a signiﬁcant difference between induced and non-arthritic controls starting around day 14. (B) Kinetics of knee BMD showing a signiﬁcant dif-
ference between groups also around day 14. (C and D) Bone volume of ankle joint ROI and BMD kinetics is illustrated. Notice that the changes to the ankle region volume happen slightly
later than knee region volume changes. There is a signiﬁcant difference between CIA-induced and non-arthritic controls detected at day 30. (E) Paw thickness increased signiﬁcantly
starting around day 14 in the CIA animals. (F) Representative images of CIA and non-arthritic paws on day 30. *, ** and *** indicate statistical signiﬁcance at p b 0.05, 0.01, and 0.001 re-
spectively, compared to non-arthritic controls.
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in Fig. 5 by day 30, CIA induced signiﬁcant bone loss in the knee and
ankle regions as demonstrated by a decrease in BMD at 472 ± 4 and
579 ± 3 mg/mL, respectively, compared to the non-arthritic controls
at 544 ± 8 mg/mL in the knee and 663 ± 8 mg/mL in the ankle. DEX
treatment signiﬁcantly reduced bone loss, as demonstrated by BMD
values in the knee and ankle of 530± 6mg/mL and 641±2mg/mL, re-
spectively, similar to the normal control BMD values (Fig. 5B). DEX
treated animals' ankle BMD was still lower than that of the disease-
free animals. The decreased BMD in the knee joint was associated
with a decrease in the bone volume (265 ± 2 mm3) in the CIA animals
compared to control knee bone volume (290 ± 6 mm3). Similar to the
cross-sectional study, the ankle bone volume in CIA animals increased
to 207 ± 2 mm3 compared to non-arthritic ankle bone volume 170 ±
3 mm3 while the ankle BMD was signiﬁcantly reduced (Figs. 5E & F).
Prednisolone was tested in this model as well as in a separate experi-
ment. The data were very similar to the results from the Dexamethasone
study except that animals treated with 3 mg/kg of Prednisolone did not
show any bone loss, such that the BMD of Prednisolone-treated CIA ani-
mals was similar to non-arthritic controls (Suppl. Figs. 2, 3).
In order to understand how the relationship between BMD reduc-
tion, inﬂammation, and BMD measurements is related to standard as-
says, we investigated the effect of Dexamethasone and Prednisoloneon paw thickness and histopathology. In the knee joint, the loss of
BMD (Fig. 5B) was associated with bone resorption, cartilage damage,
pannus formation, and inﬂammatory cell inﬁltration, as measured by
histology (Fig. 5D). Histological analysis corroborated our ﬁnding that
Dexamethasone inhibits BMD loss in knee joints. Similarly, histological
analysis of the ankle joints correlated well with BMD measurements
(Suppl. Figs. 3E–I). The end-point paw thickness measurements also
showed very good inverse correlation with ankle BMD measurements
with an R2 = 0.84.
Testing robustness of analysis techniques
When varying box sizes by ±1 × 1 × 1 mm3 for both joints, there
was no detectable difference in BMD output for ankle or knee using a
one-way ANOVA, F (2, 219) = .012, p = .988. Bonferroni corrected
post-hoc t-tests were performed on the three groups and indicate that
noneof the groupswere statistically signiﬁcant at p b .05. This is because
although the box size was varied, the placement between each size
group was consistent using the turning point of the knee and ankle to
position the bounding boxes. Given the results, we are conﬁdent that
small shifts in box placement will not negatively impact results, espe-
cially given the quality control measure of spot checking box placement
built into our analysis method.
Fig. 5. Effect of Dexamethasone on BMD and volume in the CIA model. Starting on day 17, CIA-induced rats were dosed orally QD with vehicle or Dexamethasone at 0.3 mg/kg and non-
arthritic controls were dosedwith vehicle for 2 weeks. Hind limbs were collected for BMD and histological analysis. (A) Bone volume of knee ROI depicted asmean± SEM. (B) Knee BMD
shown asmean± SEM. (C) Representative CT images of 3-D rendered knee jointwith BMD close to group averages. (D) Representative histological images of knee joints. (E) Bone volume
of ankle ROI depicted asmean±SEM. (F) Ankle BMD shown asmean±SEM. (G) Representative CT images of 3-D rendered ankle and foot. (H) Representative histological images of ankle
joints. For histological images, both knee and ankle, S indicates synovium, large arrows indicate cartilage damage, small arrows show pannus formation, and arrowheads show bone
resorption. **, *** and **** indicate statistical signiﬁcance at p b 0.01, 0.001, and 0.0001 respectively, compared to non-arthritic controls. ^^, ^^^, and ^^^^ indicate statistical signiﬁcance
at p b 0.01, 0.001, and 0.0001 respectively, compared to the CIA animals.
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39R.S. Sevilla et al. / Bone 73 (2015) 32–41In our next experiment, we measured endpoint reproducibility
using test–retest on two separate days TEST (day 0) and RETEST
(day 3) with 20 subjects. Four endpoints are considered in the analysis:
Left Knee, Right Knee, Left Ankle and Right Ankle. The quantitativemea-
sures showed great agreement between TEST and RETEST. All the
Pearson's correlation coefﬁcients are larger than 0.98 and intraclass
correlation coefﬁcients (ICC) are larger than 0.94. The Coefﬁcient of
Variance (CV) is all less than 1%, which indicates that the differences be-
tween the two measurements are very small compared to their mean
measurements. Bland–Altman showed RETEST is consistently slightly
higher than TEST, however the difference is relatively small; there is
no signiﬁcant difference between the two measurements. There is no
positive or negative systematic trend, which shows that there is no sig-
niﬁcant difference in measurement precision. In summary, all the 4 im-
aging endpoints show great reproducibility in the test–retest analysis
(Suppl. Fig. 4 and Table 1).
Discussion
In this study,we describe a high-throughputmethod of image acqui-
sition, and a novel, fully automated image analysis technique that as-
sesses bone volume and BMD of the peripheral joints in the rat CIA
model. Detection of BMD reduction in ratmodels of arthritis has provid-
ed a useful biomarker of disease that can track drug efﬁcacy. A limited
number of publications have monitored the peripheral joints in similar
animalmodels of RA, and even fewer use BMD as a biomarker of disease
to delineate therapeutic response [19–21,23,25]. Preclinical interroga-
tion of BMD in the rat CIA model [39–41] often monitors areas adjacent
to the joint, but this is an incomplete assessment since damage ﬁrst oc-
curs in and around the joint itself. A method to monitor BMD that
encompassed the entire joint was needed. We validated the use of
knee and ankle BMD to monitor disease progression with a cross-
sectional study, corroborated by histology and paw thickness measure-
ments. Drug efﬁcacy, as measured by changes in BMD and using either
Dexamethasone or Prednisolone as positive controls, was corroborated
by histology and paw thickness measurements as well. The automated
analysis method we developed was validated by comparing the mean
HU and volume with the values obtained by manual segmentation.
In the cross-sectional study, we noted that bone growth occurred as
demonstrated by an increase in knee bone volume and both knee and
ankle BMD in control animals that plateaued by week 12 (Fig. 4). The
subjects were adolescent rats and it is likely that the bone was still
growing andmaturing through the course of the study. The bodyweight
of female Lewis rats increases about 13% on average from week 8 to
week 11 based on our experience and as documented by the growth
curve from the vendor [42]. Besides body weight increase, it has been
demonstrated that bone growth rate is variable in small rodents
[43–45]. Long bone adjacent to the knee and ankle joints, in particular,
is variable. Variability lies not only within different areas of the rat skel-
eton itself, but between strains of rats [43,44]. There is also evidence
that CIA administration itself causes changes in normal bone growth
patterns [46,47]. Age of induction also seems to effect bone erosion, lo-
cation, and extent of bone damage in certain rat strains [48]. The ratio-
nale behind using growing, adolescent rats is that they tend to have
faster disease onset and have a robust, well-characterized phenotype.
Many protocols and research publications cite the use of adolescent
rats for CIA experiments [7,10,37,38,48]. We anticipate that the effect
of skeletal growth of long bone included in our volume and BMDmea-
surements is lessened since our boxes cover the entire joint. Additional-
ly, we age-match our cohorts of animals in each treatment group, so
that whatever effect growth rate of bone has on either volume or BMD
should be replicated across groups, and hopefully, effectively reduced.
Longitudinal monitoring would be challenging in this CIA model in
which disease is induced during adolescence when bone growth is
still occurring because potentially disparate anatomical areas could be
represented within the bounding box during maturation.An interesting ﬁnding was that knee bone volume change always
correlated with BMD while the ankle bone volume was inversely asso-
ciatedwith BMD. In otherwords, animalswith CIA-induced BMD reduc-
tion in the ankle showed bone volume increases (Figs. 4, 5). However,
when CIA-induced animals were treated with DEX (Fig. 5), volume
and BMD data gathered ex vivo both remain near non-arthritic levels.
The changes in BMD and volume we observed may indicate that the
bone structures themselves ﬁrst weaken and, in the ankle, expand as
bone damage occurs, accounting for the increase in volume. This is in-
teresting because while changes to bone volume were observed, the
total bone mass (as calculated by bone volume × density) was affected
to a lesser degree in the ankle (data not shown). Therefore, focusing
solely on bone mass as a biomarker would not have revealed as drastic
a change in the ankle joint. A recent publication by Kocijan et al. report-
ed that both male and female RA patients increased the perimeter of
their cortical bone in the distal radius and ultra-distal radius compared
to healthy, age-matched controls [49]. This may suggest that bone vol-
ume increase (such as in the ankle of CIA animals) has an impact on
the structural integrity of bone and causes increased fracture risk in
RA patients. It is also possible that the effects of CIA immunization itself
have altered bone growth more in certain areas than others since it has
been shown that abnormally early closure of the growth plate occurs in
the long bones in this rat CIA model [46,47], which could point to the
mechanisms leading to the differential effect between BMD and bone
volume of the knee and ankle.
The tools we have described for acquisition, reconstruction,
cropping, and automated analysis can be used for other rodent models
of arthritis and inﬂammation. They have been tested successfully in
the adjuvant-induced arthritis (AIA) and streptococcal cell wall (SCW)
rat models. By simply adjusting the box sizes, the tools can also be
used in mouse models where bone in and around the knee and ankle
joints is impacted by inﬂammation, such as mouse CIA and systemic
lupus erythematosus (SLE) mouse models.
A limitation of this analysis method is that is it not outﬁtted to per-
form analysis of the distinct osseous tissue that forms the bone. Al-
though one could use the bounding box placement feature of the
automated analysis to consistently place bounding boxes as a precursor
to any analysis method, to perform trabecular analysis, higher resolu-
tion image acquisition and incorporation of a technique to separate
bone tissue types would be required. That no preparation of hind limb
samples is required with our methods after animals are sacriﬁced and
their limbs are formalin ﬁxed is a key time savings to our automation
process, but because only hind limbs are imaged, another shortcoming
is that the automated segmentation tools cannot be directly applied to
in vivo studies without major changes. Animal positioning is error
prone with in vivo CT imaging. This presents major challenges to script
automation, including: cropping hind limbs while including other bone
structures in the ﬁeld of view, successfully identifying the curvature of
the skeleton, and recognizing the turning points of the ankle and knee
for box placement. Undoubtedly, a rat or mouse holder can be designed
to hold the legs in relatively consistent positions so that the hind limb
bones can be cropped properly such that the main skeletal structures
of interest, such as the femur, tibia and paw bones are the only bones
that remain for analysis. Development of in vivo automation is ongoing.
Due to the poor contrast between soft tissues inherent in CT technol-
ogy, the methods reported here cannot address other facets of RA dis-
ease, such as cartilage damage, inﬂammatory cell inﬁltration, and
pannus formation. However, BMD of both knee and ankle joints had
good correlation with histological analyses, indicating that BMD mea-
surements can generally reﬂect histological changes while being quan-
titative, high throughput, and less time-consuming. Clinically, MRI has
been used for arthritis examination because of its superiority in soft tis-
sue contrast [50] and at least one preclinical publication has described
anMRmethod tomonitor bone erosion in vivowith automated analysis
[29]. Further development of high throughput, preclinical MRI methods
of joint evaluation in RA animal models would be very useful.
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In summary, we have developed a high-throughput method for ac-
quisition, reconstruction, cropping, and automated image analysis to
quantify BMDof hind limb samples in RA rodentmodels. This new anal-
ysis procedure allowed us to screen therapeutic candidates using BMD
of the knee and ankle joints as a biomarker of disease progression. The
key improvements to the acquisition and analysis methods we have
outlined enabled us to implement the methods as a standard screening
assay for large studieswhile providing faster data turn-around time, ex-
cellent reproducibility, and no inter-person variability. The methods
we have detailed for monitoring joint destruction are robust, high-
throughput, and can be utilized as a routine assay for validation and op-
timization of potential anti-rheumatic agents in the rat CIA model.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2014.11.014.
Disclosure
The authors state that they have no conﬂicts of interest.
Acknowledgments
The authors wish to thank Dr. Jeffery Evelhoch for critical review of
the manuscript. All authors are either currently employed, or were
employed byMerck& Co., Inc.when experimentalworkwas completed.
Individual author contribution, in order of appearance in the author
list.
Study design: RSS, FC, CC, KC, MZ, LYM, MC, and WZ.
Data collection: RSS, KAB, JZ, KC, RF, AV, GR, MZ, JM, and EL.
Data analysis: RSS, FC, KAB, JZ, KC, RF, AV, GR, MZ, JM, and EL.
Data interpretation: CC, SW, LYM, MC, and WZ.
Software and hardware construction: DX and DC.
Automation tool development: FC, DX, and BD.
Drafting the manuscript: RSS, FC, and WZ.
Revising the manuscript content: RSS, FC, DX, KC, SW, and MC.
General editing assistance: DX, AV, GR, and BD.
Approving the ﬁnal version of the manuscript: RSS, FC, and WZ.
WZ takes responsibility for the accuracy and integrity of the
methods and data analysis.
References
[1] Harris Jr ED. Rheumatoid arthritis. Pathophysiology and implications for therapy.
N Engl J Med May 3 1990;322(18):1277–89.
[2] Redlich K, Smolen JS. Inﬂammatory bone loss: pathogenesis and therapeutic inter-
vention. Nat Rev Drug Discov Mar 2012;11(3):234–50.
[3] Goldring SR, Gravallese EM. Mechanisms of bone loss in inﬂammatory arthritis: di-
agnosis and therapeutic implications. Arthritis Res 2000;2(1):33–7.
[4] Hegen M, Keith Jr JC, Collins M, Nickerson-Nutter CL. Utility of animal models for
identiﬁcation of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis
Nov 2008;67(11):1505–15.
[5] Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimen-
tal model of arthritis. J Exp Med Sep 1 1977;146(3):857–68.
[6] Trentham DE, Townes AS, Kang AH, David JR. Humoral and cellular sensitivity to col-
lagen in type II collagen-induced arthritis in rats. J Clin Invest Jan 1978;61(1):89–96.
[7] Wagner S, Bindler J, Andriambeloson E. Animal models of collagen-induced arthritis.
Curr Protoc Pharmacol Dec 2008 [Chapter 5: Unit 5.51.1–5.51.8].
[8] Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid ar-
thritis. Clin Immunol Immunopathol Oct 1994;73(1):11–8.
[9] Bendele A. Animalmodels of rheumatoid arthritis. J Musculoskelet Neuronal Interact
Jun 2001;1(4):377–85.
[10] Caulﬁeld JP, Hein A, Dynesius-Trentham R, Trentham DE. Morphologic demonstra-
tion of two stages in the development of type II collagen-induced arthritis. Lab In-
vest Mar 1982;46(3):321–43.
[11] McQueen FM. Imaging in early rheumatoid arthritis. Best Pract Res Clin Rheumatol
Aug 2013;27(4):499–522.
[12] Yu W, Xie YZ, Jiang M, Zheng WF, Wang LH, Wang YZ, et al. CT detection of wrist
bone erosion in rheumatoid arthritis. Chin Med J (Engl) Jul 1993;106(7):509–13.
[13] Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, et al. Bonemin-
eral density in patients with rheumatoid arthritis: relation between disease severity
and low bone mineral density. Ann Rheum Dis Dec 2004;63(12):1576–80.[14] Forslind K, Keller C, Svensson B, Hafstrom I. Reduced bone mineral density in early
rheumatoid arthritis is associated with radiological joint damage at baseline and
after 2 years in women. J Rheumatol Dec 2003;30(12):2590–6.
[15] Wevers-de Boer KV, Heimans L, Visser K, Kalvesten J, Goekoop RJ, van OosterhoutM,
et al. Four-month metacarpal bone mineral density loss predicts radiological joint
damage progression after 1 year in patients with early rheumatoid arthritis: explor-
atory analyses from the IMPROVED study. Ann Rheum Dis Nov 2013;27.
[16] Ford-Hutchinson AF, Cooper DM, Hallgrimsson B, Jirik FR. Imaging skeletal patholo-
gy in mutant mice by microcomputed tomography. J Rheumatol Dec 2003;30(12):
2659–65.
[17] Finzel S, Ohrndorf S, Englbrecht M, Stach C, Messerschmidt J, Schett G, et al. A de-
tailed comparative study of high-resolution ultrasound and micro-computed to-
mography for detection of arthritic bone erosions. Arthritis Rheum May 2011;63
(5):1231–6.
[18] Silva MD, Ruan J, Siebert E, Savinainen A, Jaffee B, Schopf L, et al. Application of sur-
face roughness analysis on micro-computed tomographic images of bone erosion:
examples using a rodent model of rheumatoid arthritis. Mol Imaging Oct 2006;5
(4):475–84.
[19] Silva MD, Savinainen A, Kapadia R, Ruan J, Siebert E, Avitahl N, et al. Quantitative
analysis of micro-CT imaging and histopathological signatures of experimental ar-
thritis in rats. Mol Imaging Oct 2004;3(4):312–8.
[20] McErlain DD, Appleton CT, Litchﬁeld RB, Pitelka V, Henry JL, Bernier SM, et al. Study
of subchondral bone adaptations in a rodent surgical model of OA using in vivo
micro-computed tomography. Osteoarthritis Cartilage Apr 2008;16(4):458–69.
[21] Choi S, Lee YA, Hong SJ, Lee GJ, Kang SW, Park JH, et al. Evaluation of inﬂammatory
change and bone erosion using a murine type II collagen-induced arthritis model.
Rheumatol Int May 2011;31(5):595–603.
[22] Yang S, Hollister AM, Orchard EA, Chaudhery SI, Ostanin DV, Lokitz SJ, et al.
Quantiﬁcation of bone changes in a collagen-induced arthritis mouse model by re-
constructed three dimensional micro-CT. Biol Proced Online Jul 15 2013;15(1):8.
[23] Barck KH, LeeWP, Diehl LJ, Ross J, Gribling P, Zhang Y, et al. Quantiﬁcation of cortical
bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by
micro-computed tomography and automated image analysis. Arthritis Rheum Oct
2004;50(10):3377–86.
[24] Schneider S, Breit SM, Grampp S, Kunzel WW, Liesegang A, Mayrhofer E, et al.
Comparative assessment of bone mineral measurements obtained by use of dual-
energy X-ray absorptiometry, peripheral quantitative computed tomography, and
chemical–physical analyses in femurs of juvenile and adult dogs. Am J Vet Res Jul
2004;65(7):891–900.
[25] Stok KS, Noël D, Apparailly F, Gould D, Chernajovsky Y, Jorgensen C, et al.
Quantitative imaging of cartilage and bone for functional assessment of gene thera-
py approaches in experimental arthritis. J Tissue Eng Regen Med Jul 2010;4(5):
387–94.
[26] Huber MB, Carballido-Gamio J, Bauer JS, Baum T, Eckstein F, Lochmuller EM, et al.
Proximal femur specimens: automated 3D trabecular bone mineral density analysis
at multidetector CT—correlation with biomechanical strength measurement. Radiol-
ogy May 2008;247(2):472–81.
[27] Kohler T, Stauber M, Donahue LR, Muller R. Automated compartmental analysis for
high-throughput skeletal phenotyping in femora of genetic mouse models. Bone
Oct 2007;41(4):659–67.
[28] Waarsing JH, Day JS, Weinans H. An improved segmentation method for in vivo
microCT imaging. J Bone Miner Res Oct 2004;19(10):1640–50.
[29] Leung KK, Holden M, Saeed N, Brooks KJ, Buckton JB, Williams AA, et al. Automatic
quantiﬁcation of changes in bone in serial MR images of joints. IEEE Trans Med Im-
aging Dec 2006;25(12):1617–26.
[30] Haines BB, Bettano KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, et al. A quan-
titative volumetric micro-computed tomography method to analyze lung tumors in
genetically engineered mouse models. Neoplasia Jan 2009;11(1):39–47.
[31] Trefethen L. Spectral methods in MATLAB; 2000.
[32] mathworld.wolfram.com. [Curvature. 2-14-2014. Ref Type: Internet Communication].
[33] Nazarian A, Snyder BD, Zurakowski D, Muller R. Quantitative micro-computed to-
mography: a non-invasive method to assess equivalent bone mineral density.
Bone Aug 2008;43(2):302–11.
[34] Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, et al. A population-
based assessment of rates of bone loss at multiple skeletal sites: evidence for sub-
stantial trabecular bone loss in young adult women and men. J Bone Miner Res
Feb 2008;23(2):205–14.
[35] Krummernauer F, Doll G. Statistical methods for the comparison of measurements
derived from orthodontic imaging. Eur J Orthod 2000;22(3):257–69.
[36] Bland JM, Altman DG. Statistical methods for assessing agreement between two
methods of clinical measurement. Lancet 1986;1(8476):307–10.
[37] Takagi T, Tsao PW, Totsuka R, Suzuki T, Murata T, Takata I. Dexamethasone prevents
the decrease of bone mineral density in type II collagen-induced rat arthritis model.
Jpn J Pharmacol Oct 1998;78(2):225–8.
[38] Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant,
on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol Apr
2000;22(4):323–31.
[39] Nawata K, Enokida M, Yamasaki D, Minamizaki T, Hagino H, Morio Y, et al. Tensile
properties of rat anterior cruciate ligament in collagen induced arthritis. Ann
Rheum Dis Apr 2001;60(4):395–8.
[40] Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R. Effect of
minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats
with collagen-induced arthritis. Arthritis Rheum Jun 2003;48(6):1732–41.
[41] Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced
arthritis in rats. Rheumatology (Oxford) Mar 2012;51(3):434–42.
[42] Harlan.com. [Inbred rats— Lewis Inbred Rat. 2014. Ref Type: Internet Communication].
41R.S. Sevilla et al. / Bone 73 (2015) 32–41[43] Roach HI, Mehta G, Oreffo RO, Clarke NM, Cooper C. Temporal analysis of rat growth
plates: cessation of growth with age despite presence of a physis. J Histochem
Cytochem Mar 2003;51(3):373–83.
[44] Dawson A. The age order of epiphyseal union in the long bones of the albino rat.
Anat Rec 1925;31(1):1–17.
[45] Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an an-
imal model for osteoporosis research. Comp Med Oct 2008;58(5):424–30.
[46] Takahi K, Hashimoto J, Hayashida K, Shi K, Takano H, Tsuboi H, et al. Early closure
of growth plate causes poor growth of long bones in collagen-induced arthritis
rats. J Musculoskelet Neuronal Interact Jun 2002;2(4):344–51.
[47] Hoshino K, Hanyu T, Arai K, Takahashi HE. Mineral density and histomorphometric
assessment of bone changes in the proximal tibia early after induction of type II
collagen-induced arthritis in growing and mature rats. J Bone Miner Metab 2001;
19(2):76–83.[48] Wilson-Gerwing TD, Pratt IV, Cooper DM, Silver TI, Rosenberg AM. Age-related dif-
ferences in collagen-induced arthritis: clinical and imaging correlations. Comp
Med 2013;63(6):498–502.
[49] Kocijan R, Finzel S, Englbrecht M, Engelke K, Rech J, Schett G. Decreased quantity and
quality of the periarticular and nonperiarticular bone in patients with rheumatoid
arthritis: a cross-sectional HR-pQCT study. J Bone Miner Res Apr 2014;29(4):
1005–14.
[50] Jimenez-Boj E, Nöbauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus
AH, Kainberger F, et al. Bone erosions and bone marrow edema as deﬁned by mag-
netic resonance imaging reﬂect true bone marrow inﬂammation in rheumatoid ar-
thritis. Arthritis Rheum Apr 2007;56(4):1118–24.
